On September 3, 2024, Allarity Therapeutics, Inc. held its Annual Meeting where several key decisions were made by the stockholders. The stockholders approved an amendment to the Allarity Therapeutics Inc. 2021 Equity Incentive Plan, increasing the number of shares authorized for grant from 2,168,330 to 10,594,876. Additionally, two amendments to the company's Certificate of Incorporation were approved and subsequently filed with the Secretary of State of Delaware on September 9, 2024. The first amendment reduced the number of authorized shares from 750,500,000 to 250,500,000 and the second effected a 1-for-30 reverse stock split of the common stock, which began trading on a split-adjusted basis on the Nasdaq Capital Market on September 11, 2024. The reverse stock split resulted in every 30 shares of issued and outstanding common stock being combined...Show More

On September 3, 2024, Allarity Therapeutics, Inc. held its Annual Meeting where several key decisions were made by the stockholders. The stockholders approved an amendment to the Allarity Therapeutics Inc. 2021 Equity Incentive Plan, increasing the number of shares authorized for grant from 2,168,330 to 10,594,876. Additionally, two amendments to the company's Certificate of Incorporation were approved and subsequently filed with the Secretary of State of Delaware on September 9, 2024. The first amendment reduced the number of authorized shares from 750,500,000 to 250,500,000 and the second effected a 1-for-30 reverse stock split of the common stock, which began trading on a split-adjusted basis on the Nasdaq Capital Market on September 11, 2024. The reverse stock split resulted in every 30 shares of issued and outstanding common stock being combined into one share, with fractional shares rounded up to the next whole number. Adjustments were made to the per share exercise price and the number of shares purchasable upon exercise of outstanding stock options, as well as the number of shares reserved for future issuance under the Plan. The company's trading symbol remained 'ALLR' with a new CUSIP number post-split. During the Annual Meeting, stockholders also voted on the election of directors, the appointment of an independent auditor, and other proposals detailed in the Proxy Statement filed on August 20, 2024.